Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 13/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337830 | 0.89 | CXCR2 (0.52) | CXCR2KDM4EFYNTP53 | |
| SCHEMBL3340295 | 0.88 | CXCR2 (0.48) | CXCR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3337864 | 0.87 | CXCR2 (0.49) | CXCR2FYN | |
| SCHEMBL3336538 | 0.85 | CXCR2 (0.49) | CXCR2FYN | |
| SCHEMBL3341508 | 0.84 | CXCR2 (0.48) | CXCR2FYN | |
| SCHEMBL3340936 | 0.83 | CXCR2 (0.48) | CXCR2FYN | |
| SCHEMBL3339114 | 0.83 | CXCR2 (0.48) | CXCR2 | |
| SCHEMBL3338974 | 0.83 | CXCR2 (0.43) | CXCR2 | |
| SCHEMBL3338731 | 0.82 | CXCR2 (0.46) | CXCR2FYN | |
| SCHEMBL2638147 | 0.81 | CXCR2 (0.52) | CXCR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | claimed |
| EP-2094697-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| EP-2094697-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885KDM4E 4638/4885ALDH1A1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.